Telehealth Black Friday: Promotions That Do Not Trigger Regulators

If your clinic's Black Friday promotion went live this morning, read this before lunch. If it has not, you have a few hours to make it safer.

A discount on a prescription program is not just a price change. It is an ad, and ads about health products get read closely by regulators, competitors and patients who screenshot everything. Educational only, and no substitute for legal advice. Take your final copy to counsel who knows your state and your product.

Why does a promotion put your whole program under a microscope?

Because the promotion pulls attention to everything around it: the claims on the page, the fees at checkout, the fine print on renewal. A quiet website can sit unnoticed for months. A loud Black Friday campaign cannot.

The backdrop matters too. On September 9, 2025, the FDA announced a crackdown on misleading drug advertising, including thousands of letters warning companies and about 100 cease-and-desist letters.³ Holland & Knight reports that, unlike earlier actions, letters went to telehealth providers and companies, including GLP-1 sellers, and that products were called misbranded because of misleading ads.²

The FTC's basic standard has not moved: ads must be truthful and not misleading, and advertisers need adequate substantiation before an ad runs, whether the claim is stated or implied.¹ The September letters are broken down in The FDA's Drug Ad Crackdown Reaches Telehealth.

What is safe to run? The green list

Promote the service, not the substance.

• Extra access. Priority scheduling, a longer first visit, an added check-in message with a clinician during the first month.
• Support perks. Help with paperwork, refill reminders, a patient guide to preparing for visits.
• Education. A free webinar or guide that explains the program honestly, without claiming a result.
• A clean membership offer. A defined set of services for a defined price, with the total and the schedule shown up front.

These work because they describe what you do, which you can substantiate. They say nothing about what a drug will do for a patient.

What needs care? The yellow list

Price discounts and intro offers

A lower first-month fee is fine in principle. The risk is in the details. State exactly what the patient pays today, what they pay later, and what is not included. The FTC's staff report on dark patterns describes hidden fees as advertising only part of a price and revealing mandatory charges late in the purchase.⁴ Do not do that.

Trials and anything that renews

If an intro price becomes a recurring charge, spell out the price, the term, when it renews and exactly how to cancel. An appeals court struck down the FTC's click-to-cancel rule on July 8, 2025. Renewal offers are still governed by ROSCA, the FTC Act's ban on deceptive practices and a patchwork of state auto-renewal laws.⁵ If you would be uncomfortable explaining the renewal to a patient on the phone, rewrite it. The full checklist is in Before July 14: The Telehealth Subscription Compliance Checklist.

Testimonials and reviews

The FTC's guidance says you cannot use a testimonial to make a claim you could not substantiate directly, and a sincere personal experience is not enough because the ad still implies the product will work for others. Dramatic results need a clear disclosure of what typical users can expect, and "results not typical" alone does not fix it.¹ Paid endorsements must be clearly disclosed.¹ (Partnership ads covers the creator side.)

What safe copy sounds like

It helps to see the difference in words. Here are plain examples, written as patterns for you to adapt and have reviewed.

• Service offer: "This week, new members get a longer first visit and a follow-up check-in at no added fee. Membership is [price] per month and renews monthly. You can cancel anytime from your account or by contacting us."
• Education offer: "Join our free session on what to expect from a medical weight-management program. A licensed clinician will decide whether any treatment is appropriate for you."
• Access offer: "Book by Sunday and get priority scheduling for your first appointment."

Notice what they leave out: no drug names as selling points, no results, no comparisons, no hint of what a clinician will prescribe. The clinician decides that after an evaluation, and your copy should not decide it for them.

What should you cut? The red list

The first row is the one the FDA letters flagged (and the price story is shifting too, see GLP-1 Prices Are Falling): Holland & Knight cites examples such as "Semaglutide (the same ingredient in Wegovy & Ozempic)" and "TIRZEPATIDE (GENERIC MOUNJARO)."² The FDA announcement also called out undisclosed paid influencer promotion on social media.³

Fake urgency belongs here too. The FTC's dark patterns report lists countdown timers that suggest an offer is time-limited when it is not.⁴ If your deadline is real, say why. If it is not, remove the clock.

What does a pre-launch review look like?

Use the same checklist on every asset, in this order.

What if your promotion is already live?

Do not panic. Do a fast pass today.

• Pull any ad or email with a drug comparison or a results promise, and pause it.
• Fix checkout or landing page text that does not match the offer.
• Add the missing renewal and cancellation text.
• Send the live copy to your counsel with a note that you are tightening before the weekend.

Speed and honesty about fixing it count for a lot. An asset you corrected on Friday is better than one you defended in a regulator's letter months later.

Compliance is not the opposite of growth, and my telehealth page shows how I fold it into the funnel. It is the part of growth that lets you keep the account, the license and the trust you worked to earn.

Keep building.Ekai